Form 4 for NBP NovaBridge Biosciences
Accepted 2026-09-11 16:30:14 ET · period of report 2026-09-09 · accession 0002109966-26-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-11 16:30 | 2026-09-09 | NBP | Cao Sean Wuxiong | Chief Bus. Development Off | S - Sale | $0.74 | -108.0K | 266.5K | -29% | -$79.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-09-09 | S | D | 107,978 | $0.74 | 266,467 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. (F2) The Reporting Person sold 46,947 ADSs representing approximately 107,978 ordinary shares in connection with the partial vesting of a restricted stock unit award on September 3, 2026, solely to satisfy tax withholding obligations incurred in connection with the vesting. (F3) Reported securities are represented by 46,947 ADSs. (F4) Reported sales price represents the converted sales price of the ADSs of $1.6908. |